trial

Levetiracetam in Early Psychosis

NCTId NCT03129360
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 48 (actual)
Sponsored by NYU Langone Health
Primary completion 2021-11-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
48 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2017-08-18
Primary completion
2021-11-03
Eligibility
ALL · 16 Years · 35 Years

Interventions & indications

Drugs
Levetiracetam

Sponsors

NYU Langone HealthLead Sponsor
National Institutes of Health (NIH)Collaborator

Investigators

1
Donald C. Goff, MDPrincipal Investigator

Sites

1 total
New York, United States

Linked catalysts

1
Levetiracetam in Early Psychosis — primary completion2021-11-03

Facts & assertions

4 sourced
Enrollment
48
Phase
PHASE2
Primary Completion Date
2021-11-03
Status
COMPLETED
relationships
The graph out of here
drug
Levetiracetam
drug
lead_sponsor
NYU Langone Health
company
collaborator
National Institutes of Health (NIH)
company
indication
Schizo Affective Disorder
indication
Schizophreniform
indication
Psychosis
indication
investigator
Donald C. Goff, MD
person